Together with our partners in academia and industry, InSphero advances drug discovery and our understanding of healthy and diseased human biology pioneering the 3D in vitro cell-culture and organ-on-a-chip technologies, an inspired combination of bioengineering, micro-technologies, and computational approaches. Discover how we can help propel your drug research programs forward.
InSphero is a global pioneer in 3D in-vitro toxicology and drug discovery using state-of-the-art organ emulating technologies.
Screen and test efficacy of NAFLD and NASH drugs with a platform that mimics the disease progression in patients.
Conduct type 1 & type 2 diabetes research in a platform that ensures uniform, long-lived islets with robust functionality.
Reflect complex 3D tumor microenvironments with tumor, stromal, and immune components.
Our 3D InSight™ platforms include everything you need to optimize your investment in 3D in vitro cell technology: physiologically relevant microtissue models, specially formulated media, 3D assay protocols, and expert support from experienced application scientists. Whether you want to leverage our innovative assay-ready 3D technology in-house or partner with us on longer-term collaborative research projects to investigate complex diseases, we can propel your drug discovery and safety testing programs forward.
Why Partner with InSphero?
Add the pioneer in 3D cell-based assay solutions and scaffold-free organ-on-a-chip technology to your drug R&D team and see immediate results.
Work with 3D platforms precisely engineered to mimic human biology and save you years of model development and assay testing time.
Rely on functionally robust, highly standardized microtissue models and 3D-optimized experimental programs. InSphero is ISO 9001:2015 certified and committed to your success.
Ensure reproducible data and minimize confounding factors — regardless of the scale and complexity of your experimental programs.
“Addressing complex diseases requires the rare combination of pioneering innovation and biomedical expertise. As our discovery partner, InSphero gives us immediate access to new 3D in vitro technologies, such as organ-on-a-chip systems, that provide deep mechanistic insights into complex diseases. They have become part of our research team, committed to helping us find a cure for type 1 diabetes.”
MATTHIAS VON HERRATH, MD
Professor and Director of the Center for Type 1 Diabetes Research
La Jolla Institute of Immunology
Vice President and Senior Medical Officer